J&J Loses Ruling Over Patent for Prostate Cancer Drug Zytiga

(Bloomberg) -- Johnson & Johnson’s patent on the prostate-cancer drug Zytiga is invalid, a federal judge in New Jersey ruled Friday, clearing the way for generic competitors.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.